Belize - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Belize was 48.40 as of 2020. Its highest value over the past 30 years was 48.40 in 2020, while its lowest value was 41.20 in 1991.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 42.90
1991 41.20
1992 42.10
1993 42.50
1994 42.90
1995 43.60
1996 44.10
1997 44.50
1998 44.70
1999 44.90
2000 45.10
2001 45.20
2002 45.20
2003 45.30
2004 45.30
2005 45.40
2006 45.60
2007 45.70
2008 46.00
2009 46.30
2010 46.70
2011 47.00
2012 47.30
2013 47.50
2014 47.60
2015 47.90
2016 48.10
2017 48.10
2018 48.30
2019 48.40
2020 48.40

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors